πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

70 results for β€œautologous” Clear

  1. A Phase I Interventional Open-Label, Non-Randomized Dose-Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-Tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients with Selected Advanced Cancers. Catherine Trial

    The George Institute

    Locally advanced, recurrent, or metastatic breast, gastric, endometrial, and selected other solid tumors with positive expression for HER-2 (3+)

    phase 1 other active

    1 trial

  2. Autologous Bone Marrow-derived Mononuclear Cells

    Regeneron Ireland Designated Activity Company (DAC)

    Congenital Heart Disease

    phase 1 mab completed

    1 trial

  3. Autologous Engineered Urethral Construct

    United Therapeutics Europe Ltd

    Urologic Diseases

    phase 1 mab active

    1 trial

  4. Autologous Human Schwann Cell

    United Therapeutics Europe Ltd

    Peripheral Nerve Injury

    phase 1 mab active

    1 trial

  5. Autologous Natural Killer Cell Therapy

    Hospital Authority, Hong Kong

    Hepatocellular Carcinoma

    phase 1 small molecule active

    1 trial

  6. Autologous differentiated myocyte transplantation

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Metabolic Disease

    phase 1 mab active

    1 trial

  7. Autologous mononuclear cells

    Regeneron Ireland Designated Activity Company (DAC)

    Congenital Heart Disease, SRV Dependent

    phase 1 mab active

    1 trial

  8. Autologous tissue engineered corpora

    United Therapeutics Europe Ltd

    Urologic Diseases

    phase 1 mab active

    1 trial

  9. Autologous tolerogenic dendritic cells (ATDC) for highly sensitized kidney transplant recipients

    The George Institute

    Kidney trasplants

    phase 1 other active

    1 trial

  10. Autologous tumor-infiltrating lymphocyte cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Solid Tumor

    phase 1 mab terminated

    1 trial

  11. Autologous Ξ³Ξ΄T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-Hodgkin's Lymphoma

    phase 1 mab active

    1 trial

  12. Biological/Vaccine: therapeutic autologous dendritic cells.

    LISATA THERAPEUTICS, INC.

    Kidney Cancer

    phase 1 mab terminated

    1 trial

  13. Pembrolizumab plus autologous dendritic cell vaccine in patients with advanced mesothelioma who have failed prior therapies

    Istituto Gentili S.r.l.

    Mesothelioma

    phase 1 other active

    1 trial

  14. RESTART; Autologous Transplantation of Adult Salivary Gland Stem Cells to Restore Submandibular Gland Function after Radiotherapy

    Disc Medicine

    Patients operated with curative intend for head and neck cancer with an indication for bilateral postoperative radiotherapy, with or without chemotherapy.

    phase 1 other active

    1 trial

  15. autologous ET1402L1-CART cells

    AEON Biopharma

    Hepatocellular Carcinoma

    phase 1 mab terminated

    1 trial

  16. autologous FL-33 CAR T therapy

    Universal Integrated

    Refractory/Relapsed Acute Myeloid Leukaemia

    phase 1 small molecule active

    1 trial

  17. autologous cell-based delivery

    Regeneron Ireland Designated Activity Company (DAC)

    Hypoplastic Left Heart Syndrome

    phase 1 mab completed

    1 trial

  18. autologous decidual-like NK cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Abortion, Habitual

    phase 1 mab active

    1 trial

  19. engineered autologous T cells

    United Therapeutics Europe Ltd

    Prostate Cancer

    phase 1 mab active

    1 trial

  20. Senl_B19 autologous CAR-T (S1904) treatment

    The First People's Hospital of Lianyungang

    Relapsed Adult ALL

    mab active

    1 trial

  21. modified BEAM

    The First People's Hospital of Lianyungang

    Autologous Stem Cell Transplantation

    small molecule active

    1 trial

  22. Ξ³-globin reactivated autologous hematopoietic stem cells

    The First People's Hospital of Lianyungang

    Thalassemia Major

    mab on hold

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources